Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
Research topic Preoperative efficacy and safety of pyrrolitinib combined with trastuzumab and
AI in the treatment of HR+/HER2+breast cancer Overall: A single arm multicenter phase II
exploratory study。Subjects HR+/HER2+breast cancer patients in stage Ⅱ~Ⅲ A。
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital